NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic ...

There is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain stimulator that ... multi-center trial to test the device.

Referring to Section 41 of Code of Criminal Procedure (CrPC), he said it was ... he said while criticising the ongoing trend of trial on social media. "Every citizen has right to criticise judgements.

Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, has recently undergone significant changes in its market position ...

Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence (“AI”) Powered BCI ...

Migraine disrupts daily life with invisible neurological pain, causing physical, emotional, and cognitive struggles that go ...

The DPP is under pressure to explain why it suddenly dropped 100 charges against an alleged domestic violence perpetrator ...

A group of researchers at .NeuroRestore has recently created a system that seamlessly combines rehabilitation robots with an ...